Get the Stockscreener App
66.85
10.06%
6.11
After Hours:
67.14
0.29
+0.43%
Sol Gel Technologies Ltd stock is traded at $66.85, with a volume of 26,065.
It is up +10.06% in the last 24 hours and down -18.20% over the past month.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
See More
Previous Close:
$60.74
Open:
$61.25
24h Volume:
26,065
Relative Volume:
0.49
Market Cap:
$218.87M
Revenue:
$18.47M
Net Income/Loss:
$-1.05M
P/E Ratio:
-190.29
EPS:
-0.3513
Net Cash Flow:
$-33.87M
1W Performance:
+11.42%
1M Performance:
-18.20%
6M Performance:
-15.45%
1Y Performance:
+138.84%
1-Day Range:
$61.05
$67.29
1-Week Range:
$58.30
$67.29
52-Week Range:
$27.00
$97.97
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Name
Sol Gel Technologies Ltd
Sector
Industry
Phone
-
Address
-
Compare SLGL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
66.85 | 218.87M | 18.47M | -1.05M | -33.87M | -0.3513 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Dec-31-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-19 | Reiterated | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd Stock (SLGL) Latest News
Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study - TipRanks
Sol-Gel completes phase 3 trial for Gorlin syndrome treatment - Investing.com
Sol-Gel completes phase 3 trial for Gorlin syndrome treatment By Investing.com - Investing.com Nigeria
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - finance.yahoo.com
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome - marketscreener.com
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial - TipRanks
Sol-Gel Technologies (SLGL) hits key Phase 3 Gorlin milestone - Stock Titan
A skin-cancer trial reaches its final visit. Sol-Gel expects results in late November. - Stock Titan
Opaleye Management Inc. Adds Sol-Gel Technologies Ltd (SLGL) -- Shares Look 968% Overvalued on GF Value - GuruFocus
Opaleye Management Increases Stake in Sol-Gel Technologies with 9,976 Shares Bought (NASDAQ: SLGL) - Kalkine Media
Sol-Gel Technologies: Phase 3 Gorlin Results Could Be The Next Major Catalyst - RTTNews
Sol Gel Technologies Ltd (NASDAQ: SLGL) Stock Price, News & Analysis - Kalkine
CollPlant Biotechnologies LtdADR Peer Comparison – Compare with Others - Value Research
Opaleye Management Inc. Adds to Sol-Gel Technologies Ltd (SLGL) - GuruFocus
Sol-Gel Technologies (SLGL) Consolidates Near $70.1 Within Established Trading RangeMoney Flow - dars.gov.et
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
Enlivex Therapeutics Ltd.ADR Peer Comparison – Compare with Others - Value Research
SLGL Q2 2026 Earnings: Loss Narrows Sharply on 52% EPS Beat, Yet Shares Slip 5.18%EPS Growth Rate - careplusvn.com
LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $195 - Moomoo
Sol-Gel (SLGL) Snapshot: Closes 0.97% Lower at $77.73 for the Current Session; Price Setup: the $73.84 to $81.62 Range Remains in Focus in the Latest ReadingSuperTrend - vinanet.vn
Sol Gel Tech earnings beat by $2.20, revenue fell short of estimates - Investing.com India
Sol-Gel Technologies: Runway To Fund Cash Requirements Into 1Q 2028 >SLGL - Moomoo
Sol-Gel reports $0.6M Q2 revenue as SGT-610 trial advances - grafa.com
symbol__ Stock Quote Price and Forecast - CNN
Sol-Gel Technologies Releases Q2 2026 Financial Results - AlphaStreet
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout - TipRanks
Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS - MarketBeat
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Sol-Gel Technologies (NASDAQ: SLGL) sees cash runway into Q1 2028 - Stock Titan
SLGL Q1 2026 Earnings: Narrower Loss Beats Estimate, Shares Slip 2.83%Annual Report - dars.gov.et
Opaleye Management Reports Acquisition of Sol-Gel Technologies Shares - Kalkine Media
Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday - MarketBeat
ELDN Stock Price and Chart — NASDAQ:ELDN - TradingView
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sol-Gel Technologies Q1 2026 Earnings: Narrower Loss Delivers 30.2% EPS Beat, Yet Shares Slip 6.04%Earnings Call Q&A - dars.gov.et
Sol Gel Technologies Ltd (SLGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sol-Gel Technologies (SLGL) Edges Lower by 0.79% as Shares Hold Above $79.78 SupportAscending Triangle - careplusvn.com
Sol-Gel Technologies (SLGL) Edges Lower as Stock Tests Key Support ZoneTurnaround Stocks - vinanet.vn
Sol Gel Technologies Ltd (SLGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SLGL|Sol Gel Technologies Ltd|Price:79.230|Chg%:-0.600 - TradingKey
Sol Gel Technologies Ltd (SLGL) Cash Flow - TradingKey
Sol Gel Technologies Ltd (SLGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sol Gel Technologies Ltd (SLGL) Institutional Confidence - TradingKey
TradingKey - TradingKey
Sol-Gel Technologies (SLGL) Climbs 2.17% as Bulls Test Resistance Near $86RVOL Spike - dars.gov.et
Sol-Gel Technologies Ltd. Revenue Breakdown – NASDAQ:SLGL - tradingview.com
Sol-Gel Technologies Ltd. Revenue Breakdown – FWB:4SG - TradingView
Sol Gel Technologies Ltd (SLGL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SLGL Q2'26 Earnings: revenue estimate is 75.00K USD - tradingview.com
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunit - Benzinga
Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd - GuruFocus
Sol Gel Technologies Ltd Stock (SLGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):